iwAL 2022 | New frontiers in ALL – MRD for clinical practice
Robin Foà and Sabina Chiaretti
• 29 Sep 2022
Sabina Chiaretti, MD, PhD, and Robin Foà, MD, Sapienza University of Rome, Rome, Italy, discuss the use of measurable residual disease (MRD) in clinical practice for acute lymphoblastic leukemia (ALL). This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
